Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

Gunther Nussbaumer(Medical University of Graz), Martin Benesch(Medical University of Graz), Yura Grabovska(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), David Castel(Inserm), Jacques Grill(Inserm), Marta M. Alonso(Navarre Institute of Health Research), Manila Antonelli(Sapienza University of Rome), Simon Bailey(Royal Victoria Infirmary), Joshua Baugh(Princess Máxima Center), Veronica Biassoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Mirjam Blattner-Johnson(German Cancer Research Center), Alberto Broniscer(Children's Hospital of Pittsburgh), Andrea Carai(Bambino Gesù Children's Hospital), Giovanna Stefania Colafati(Bambino Gesù Children's Hospital), Niclas Colditz(Universitätsmedizin Göttingen), Selim Corbacioglu(University of Regensburg), Shauna Crampsie(Institute of Cancer Research), Natacha Entz‐Werlé(Centre National de la Recherche Scientifique), Matthias Eyrich(Universitätsklinikum Würzburg), Lea L Friker(University of Bonn), Michael C. Frühwald(University Hospital Augsburg), Maria Luisa Garrè(Istituto Giannina Gaslini), Nicolas U. Gerber(University Children's Hospital Zurich), Felice Giangaspero(Sapienza University of Rome), Maria João Gil‐da‐Costa(Hospital de São João), Norbert Graf(Saarland University), Darren Hargrave(Great Ormond Street Hospital), Péter Hauser(Semmelweis University), Ulrich Herrlinger(University Hospital Bonn), Marion Hoffmann(Universitätsmedizin Göttingen), Esther Hulleman(Princess Máxima Center), Elisa Izquierdo(Institute of Cancer Research), Sandra Jacobs(KU Leuven), Michael Karremann(Heidelberg University), Antonis Kattamis(National and Kapodistrian University of Athens), Rejin Kebudi(Istanbul University), Rolf‐Dieter Kortmann(Leipzig University), Robert Kwiecien(University of Münster), Maura Massimino(Fondazione IRCCS Istituto Nazionale dei Tumori), Angela Mastronuzzi(Bambino Gesù Children's Hospital), Evelina Miele(Bambino Gesù Children's Hospital), Giovanni Morana(University of Turin), Claudia M Noack, Virve Pentikäinen(Helsinki University Hospital), Thomas Perwein(Medical University of Graz), Stefan M. Pfister(German Cancer Research Center), Torsten Pietsch(University of Bonn), Kleoniki Roka(National and Kapodistrian University of Athens), Sabrina Rossi(Bambino Gesù Children's Hospital), Stefan Rutkowski(Universität Hamburg), Elisabetta Schiavello(Fondazione IRCCS Istituto Nazionale dei Tumori), Clemens Seidel(Leipzig University), Jaroslav Štěrba(Masaryk University), Dominik Sturm(German Cancer Research Center), David Sumerauer(Charles University), Anna Tacke(Universitätsmedizin Göttingen), Sara Temelso(Institute of Cancer Research), Chiara Valentini(University Hospital Carl Gustav Carus), Dannis G. van Vuurden(Princess Máxima Center), Pascale Varlet(Centre Hospitalier Sainte-Anne), Sophie E. M. Veldhuijzen van Zanten(Erasmus MC), Maria Vinci(Bambino Gesù Children's Hospital), André O. von Bueren(University Hospital of Geneva), Monika Warmuth‐Metz(University of Würzburg), Pieter Wesseling(Princess Máxima Center), Maria Wiese(Bambino Gesù Children's Hospital), Johannes Wolff(AbbVie (United States)), Josef Zámečnı́k(Charles University), Andrés Morales La Madrid(Hospital Sant Joan de Déu Barcelona), Brigitte Bison(University of Augsburg), Gerrit H. Gielen(University of Bonn), David Jones(German Cancer Research Center), Chris Jones(Institute of Cancer Research), Christof M. Kramm(Universitätsmedizin Göttingen)
Neuro-Oncology
May 8, 2024
Cited by 11Open Access
Full Text

Abstract

BACKGROUND: The term gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features could not be established. METHODS: We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. RESULTS: Median overall survival (OS) was 15.5 months (interquartile range, 10.9-27.7) with a 2-year survival rate of 28%. Histopathological grading correlated significantly with median OS: CNS WHO grade II: 47.8 months (25.2-55.7); grade III: 15.9 months (11.4-26.3); grade IV: 10.4 months (8.8-14.4). By DNA methylation profiling (n = 49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wild-type (n = 31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n = 19), pedHGG_A/B (n = 6), and pedHGG_MYCN (n = 5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wild-type subgroup, recurrent alterations in EGFR (n = 10) and BCOR (n = 9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wild-type subgroup TP53 alterations had a significant negative effect on OS. CONCLUSIONS: Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).


Related Papers